M1 disease detected with PSMA-PET in 46 percent of patients with high-risk, nonmetastatic hormone-sensitive prostate cancer.

The centre will leverage fully automated lesion segmentation in PSMA-PET/CT imaging. Malaysia’s Sunway Medical Centre, Sunway ...

These services include specialized options tailored to various cancer types. The PSMA PET CT scan is designed for prostate ...

PSMA PET scans enable precise detection of prostate cancer even in its earliest stages, improving diagnostic accuracy and ...

Telix Pharma’s prostate cancer PET1 imaging agent, Illuccix receives European marketing approval: Melbourne, Australia Saturday, January 18, 2025, 10:00 Hrs [IST] Telix Pharmace ...

Telix Pharmaceuticals Limited today announces that it has received a positive decision on the Marketing Authorization ...

PSMA-PET/CT findings were positive in 84% of the patients. PSMA-PET/CT detected distant metastatic disease in 46% of patients, including 34% of patients after RP, 56% after definitive RT, and 60% ...

Prostate cancer stands as the third most common cancer among Malaysian men, with 70 percent of cases diagnosed at advanced ...

THURSDAY, Jan. 9, 2025 (HealthDay News) -- Among patients with high-risk prostate cancer and no evidence of metastatic disease on conventional imaging, prostate-specific membrane antigen-positron ...

New imaging technique has shown that many cases of prostate cancer may be more advanced than conventional imaging suggests. Read on!

Researchers conducted a post hoc, retrospective, cross-sectional analysis of 182 patients with recurrent prostate cancer after radical prostatectomy, definitive radiotherapy, or salvage radiotherapy.